Wild-type c-KIT expressing GIST and KIT-mutated melanoma represent minority subgroups of their respective diseases [19–21] with limited treatment options, highlighting the need for new therapeutic developments. This evidence concerns the gene KIT and gastrointestinal stromal tumor.